|
시장보고서
상품코드
1977894
원료의약품 CDMO 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)Global Active Pharmaceutical Ingredient CDMO Market Size, Share, Trends & Growth Analysis Report 2026-2034 |
||||||
원료의약품(API) 위탁개발 제조(CDMO) 시장 규모는 2025년 978억 7,000만 달러에서 2026년부터 2034년까지 CAGR 7.68%로 성장하여 2034년에는 1,904억 9,000만 달러에 달할 것으로 예측됩니다.
세계 원료의약품 CDMO 시장은 제약사들의 아웃소싱 증가로 인해 강력한 성장세를 보이고 있습니다. 위탁개발생산기관(CDMO)은 API 개발, 스케일업, 상업생산에 대한 전문적인 노하우를 제공합니다. 의약품 개발 활동의 활성화와 비용 효율적인 제조 솔루션에 대한 수요 증가가 시장 확대를 견인하고 있습니다.
주요 성장 요인으로는 의약품 분자의 복잡성, 바이오의약품 생산 확대, 규제 준수 요건 강화 등을 들 수 있습니다. 제약사들은 시장 출시 기간 단축과 운영 비용 최적화를 위해 CDMO와의 제휴를 추진하고 있습니다. 또한, 제네릭 의약품 및 특수 의약품 제조에 대한 투자 증가도 수요를 뒷받침하고 있습니다.
맞춤형 의료와 고효능 API에 대한 관심이 높아지는 가운데, 향후 전망은 여전히 밝습니다. 신흥 시장에서의 제조 시설 확장은 큰 성장 기회를 제공합니다. 공정 최적화와 품질 관리의 지속적인 혁신이 시장 경쟁력을 강화할 것입니다. 세계 제약 연구개발이 계속 확대되는 가운데, API CDMO 시장은 장기적으로 안정적인 성장을 유지할 것으로 예상됩니다.
목차
제1장 소개
제2장 주요 요약
제3장 시장 변수, 동향, 프레임워크
제4장 세계의 원료의약품 CDMO 시장 : 제품별
제5장 세계의 원료의약품 CDMO 시장 : 합성 방식별
제6장 세계의 원료의약품 CDMO 시장 : 약물별
제7장 세계의 원료의약품 CDMO 시장 : 워크플로우별
제8장 세계의 원료의약품 CDMO 시장 : 용도별
제9장 세계의 원료의약품 CDMO 시장 : 지역별
제10장 경쟁 구도
제11장 기업 개요
KSM 26.04.07The Active Pharmaceutical Ingredient CDMO Market size is expected to reach USD 190.49 Billion in 2034 from USD 97.87 Billion (2025) growing at a CAGR of 7.68% during 2026-2034.
The Global Active Pharmaceutical Ingredient CDMO Market is experiencing strong growth due to increasing outsourcing by pharmaceutical companies. Contract development and manufacturing organizations (CDMOs) provide specialized expertise in API development, scale-up, and commercial production. Rising drug development activities and growing demand for cost-efficient manufacturing solutions are driving market expansion.
Major growth drivers include increasing complexity of drug molecules, expansion of biologics production, and regulatory compliance requirements. Pharmaceutical companies are partnering with CDMOs to accelerate time-to-market and optimize operational costs. Additionally, growing investment in generic and specialty drug manufacturing supports demand.
Future prospects remain positive with rising focus on personalized medicine and high-potency APIs. Expansion of manufacturing facilities in emerging markets offers significant growth opportunities. Continuous innovation in process optimization and quality control will strengthen market competitiveness. As pharmaceutical R&D continues to grow globally, the API CDMO market is expected to maintain steady long-term expansion.
Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:
Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.
Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.
Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.
Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.
Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.
Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.
Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.
MARKET SEGMENTATION
By Product
- Traditional Active Pharmaceutical Ingredient (Traditional API)
- Highly Potent Active Pharmaceutical Ingredient (HP-API)
- Antibody Drug Conjugate (ADC)
- Others
By Synthesis
- Synthetic
- Biotech
By Drug
- Innovative
- Generics
By Workflow
- Clinical
- Commercial
By Application
- Oncology
- Hormonal
- Glaucoma
- Cardiovascular Disease
- Diabetes
- Others
COMPANIES PROFILED
- Cambrex Corporation, Recipharm AB, Thermo Fisher Scientific Inc Pantheon, CordenPharma International, Samsung Biologics, Lonza, Catalent Inc, Siegfried Holding AG, Piramal Pharma Solutions, Boehringer Ingelheim International GmbH
- We can customise the report as per your requirements.
TABLE OF CONTENTS
Chapter 1. PREFACE
- 1.1. Market Segmentation & Scope
- 1.2. Market Definition
- 1.3. Information Procurement
- 1.3.1 Information Analysis
- 1.3.2 Market Formulation & Data Visualization
- 1.3.3 Data Validation & Publishing
- 1.4. Research Scope and Assumptions
- 1.4.1 List of Data Sources
Chapter 2. EXECUTIVE SUMMARY
- 2.1. Market Snapshot
- 2.2. Segmental Outlook
- 2.3. Competitive Outlook
Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK
- 3.1. Market Lineage Outlook
- 3.2. Penetration & Growth Prospect Mapping
- 3.3. Value Chain Analysis
- 3.4. Regulatory Framework
- 3.4.1 Standards & Compliance
- 3.4.2 Regulatory Impact Analysis
- 3.5. Market Dynamics
- 3.5.1 Market Drivers
- 3.5.2 Market Restraints
- 3.5.3 Market Opportunities
- 3.5.4 Market Challenges
- 3.6. Porter's Five Forces Analysis
- 3.7. PESTLE Analysis
Chapter 4. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENT CDMO MARKET: BY PRODUCT 2022-2034 (USD MN)
- 4.1. Market Analysis, Insights and Forecast Product
- 4.2. Traditional Active Pharmaceutical Ingredient (Traditional API) Estimates and Forecasts By Regions 2022-2034 (USD MN)
- 4.3. Highly Potent Active Pharmaceutical Ingredient (HP-API) Estimates and Forecasts By Regions 2022-2034 (USD MN)
- 4.4. Antibody Drug Conjugate (ADC) Estimates and Forecasts By Regions 2022-2034 (USD MN)
- 4.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)
Chapter 5. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENT CDMO MARKET: BY SYNTHESIS 2022-2034 (USD MN)
- 5.1. Market Analysis, Insights and Forecast Synthesis
- 5.2. Synthetic Estimates and Forecasts By Regions 2022-2034 (USD MN)
- 5.3. Biotech Estimates and Forecasts By Regions 2022-2034 (USD MN)
Chapter 6. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENT CDMO MARKET: BY DRUG 2022-2034 (USD MN)
- 6.1. Market Analysis, Insights and Forecast Drug
- 6.2. Innovative Estimates and Forecasts By Regions 2022-2034 (USD MN)
- 6.3. Generics Estimates and Forecasts By Regions 2022-2034 (USD MN)
Chapter 7. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENT CDMO MARKET: BY WORKFLOW 2022-2034 (USD MN)
- 7.1. Market Analysis, Insights and Forecast Workflow
- 7.2. Clinical Estimates and Forecasts By Regions 2022-2034 (USD MN)
- 7.3. Commercial Estimates and Forecasts By Regions 2022-2034 (USD MN)
Chapter 8. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENT CDMO MARKET: BY APPLICATION 2022-2034 (USD MN)
- 8.1. Market Analysis, Insights and Forecast Application
- 8.2. Oncology Estimates and Forecasts By Regions 2022-2034 (USD MN)
- 8.3. Hormonal Estimates and Forecasts By Regions 2022-2034 (USD MN)
- 8.4. Glaucoma Estimates and Forecasts By Regions 2022-2034 (USD MN)
- 8.5. Cardiovascular Disease Estimates and Forecasts By Regions 2022-2034 (USD MN)
- 8.6. Diabetes Estimates and Forecasts By Regions 2022-2034 (USD MN)
- 8.7. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)
Chapter 9. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENT CDMO MARKET: BY REGION 2022-2034(USD MN)
- 9.1. Regional Outlook
- 9.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
- 9.2.1 By Product
- 9.2.2 By Synthesis
- 9.2.3 By Drug
- 9.2.4 By Workflow
- 9.2.5 By Application
- 9.2.6 United States
- 9.2.7 Canada
- 9.2.8 Mexico
- 9.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
- 9.3.1 By Product
- 9.3.2 By Synthesis
- 9.3.3 By Drug
- 9.3.4 By Workflow
- 9.3.5 By Application
- 9.3.6 United Kingdom
- 9.3.7 France
- 9.3.8 Germany
- 9.3.9 Italy
- 9.3.10 Russia
- 9.3.11 Rest Of Europe
- 9.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
- 9.4.1 By Product
- 9.4.2 By Synthesis
- 9.4.3 By Drug
- 9.4.4 By Workflow
- 9.4.5 By Application
- 9.4.6 India
- 9.4.7 Japan
- 9.4.8 South Korea
- 9.4.9 Australia
- 9.4.10 South East Asia
- 9.4.11 Rest Of Asia Pacific
- 9.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
- 9.5.1 By Product
- 9.5.2 By Synthesis
- 9.5.3 By Drug
- 9.5.4 By Workflow
- 9.5.5 By Application
- 9.5.6 Brazil
- 9.5.7 Argentina
- 9.5.8 Peru
- 9.5.9 Chile
- 9.5.10 South East Asia
- 9.5.11 Rest of Latin America
- 9.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
- 9.6.1 By Product
- 9.6.2 By Synthesis
- 9.6.3 By Drug
- 9.6.4 By Workflow
- 9.6.5 By Application
- 9.6.6 Saudi Arabia
- 9.6.7 UAE
- 9.6.8 Israel
- 9.6.9 South Africa
- 9.6.10 Rest of the Middle East And Africa
Chapter 10. COMPETITIVE LANDSCAPE
- 10.1. Recent Developments
- 10.2. Company Categorization
- 10.3. Supply Chain & Channel Partners (based on availability)
- 10.4. Market Share & Positioning Analysis (based on availability)
- 10.5. Vendor Landscape (based on availability)
- 10.6. Strategy Mapping
Chapter 11. COMPANY PROFILES OF GLOBAL ACTIVE PHARMACEUTICAL INGREDIENT CDMO INDUSTRY
- 11.1. Top Companies Market Share Analysis
- 11.2. Company Profiles
- 11.2.1 Cambrex Corporation
- 11.2.2 Recipharm AB
- 11.2.3 Thermo Fisher Scientific Inc. (Pantheon)
- 11.2.4 CordenPharma International
- 11.2.5 Samsung Biologics
- 11.2.6 Lonza
- 11.2.7 Catalent Inc
- 11.2.8 Siegfried Holding AG
- 11.2.9 Piramal Pharma Solutions
- 11.2.10 Boehringer Ingelheim International GmbH
